Mobile Site ›

What the FDA Relabeling of Abacavir Means for You and Your Patient



Information for Patients5

Slide 19

November 2008

Providers can also inform the patients that they are at lower risk of a serious hypersensitivity reaction when taking abacavir, however, hypersensitivity reaction can still occur because a negative test result is not 100% predictive.

Finally, patients with unknown HLA-B*5701 status should be tested prior to reinitiating abacavir treatment, even if they tolerated abacavir previously.

Information for Patients5

 


Jump to section:


Key